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Heterodimers of photoreceptor-specific nuclear
receptor (PNR/NR2E3) and peroxisome
proliferator-activated receptor-γ (PPARγ) are disrupted
by retinal disease-associated mutations
Joel Fulton1, Bismoy Mazumder1, Jonathan B Whitchurch1, Cintia J Monteiro1, Hilary M Collins1, Chun M Chan1, Maria P Clemente1,
Miguel Hernandez-Quiles1, Elizabeth A Stewart2, Winfried M Amoaku2, Paula M Moran3, Nigel P Mongan4,5, Jenny L Persson6,7,
Simak Ali8 and David M Heery*,1
Photoreceptor-specific nuclear receptor (PNR/NR2E3) and Tailless homolog (TLX/NR2E1) are human orthologs of the NR2E group,
a subgroup of phylogenetically related members of the nuclear receptor (NR) superfamily of transcription factors. We assessed the
ability of these NRs to form heterodimers with other members of the human NRs representing all major subgroups. The TLX
ligand-binding domain (LBD) did not appear to form homodimers or interact directly with any other NR tested. The PNR LBD was
able to form homodimers, but also exhibited robust interactions with the LBDs of peroxisome proliferator-activated receptor-γ
(PPARγ)/NR1C3 and thyroid hormone receptor b (TRb) TRβ/NR1A2. The binding of PNR to PPARγ was specific for this paralog, as
no interaction was observed with the LBDs of PPARα/NR1C1 or PPARδ/NR1C2. In support of these findings, PPARγ and PNR were
found to be co-expressed in human retinal tissue extracts and could be co-immunoprecipitated as a native complex. Selected
sequence variants in the PNR LBD associated with human retinopathies, or a mutation in the dimerization region of PPARγ LBD
associated with familial partial lipodystrophy type 3, were found to disrupt PNR/PPARγ complex formation. Wild-type PNR, but not
a PNR309G mutant, was able to repress PPARγ-mediated transcription in reporter assays. In summary, our results reveal novel
heterodimer interactions in the NR superfamily, suggesting previously unknown functional interactions of PNR with PPARγ and
TRβ that have potential importance in retinal development and disease.
Cell Death and Disease (2017) 8, e2677; doi:10.1038/cddis.2017.98; published online 16 March 2017
Nuclear receptors (NRs) are a superfamily of gene regulators
controlling a range of physiological processes and develop-
mental pathways.1 Most NRs possess a zinc-finger DNA-
binding domain (DBD) for target gene recognition and a
ligand-binding domain (LBD) that facilitates homo- or hetero-
dimeric interactions of NRs, agonist/antagonist responsive-
ness and transcriptional regulation via cofactor recruitment.
Ligands control the activity of many NRs by inducing
conformational changes in the LBD to favor coactivator or
corepressor recruitment, although true orphan NRs appear to
lack ligand regulation. NR cofactors contain amphipathic
α-helices comprising signature LXXLL or LXXI/LXXXI/L motifs
that dock with the LBD surface.2–5 Although steroid receptors
and some orphan NRs function principally as homodimers,
many NRs including peroxisome proliferator-activated
receptors (PPARs), RARs, VDR and TRs form heterod-
imers with RXRs. Heterodimer formation impacts on NR
functions by altering their preference for specific DNA target
sequences, as well as ligand response and interactions with
cofactors.6–8 However, systematic studies of the dimerization
properties of human NRs, in particular the orphan NRs, are
incomplete.9
TLXandphotoreceptor-specificNR (PNR) aremembers of the
NR2E orphan receptor subgroup that are most closely related
to the COUPTF (NR2F) and RXR (NR2B) subgroups.10 In
mammals, TLX/NR2E1 is expressed in neurogenic regions of
the brain and the retina, where it regulates neural stem cell
maintenance and neocortex development. Deletion of the TLX
gene inmice is associatedwith a pathological aggression (fierce)
phenotype in addition to retinal dystrophy.11–14 PNR/NR2E3 is
required for photoreceptor development and function,15,16 and its
expression in adults is restricted to the outer nuclear layer of the
neurosensory retina, where it functions to repress cone genes
and commit photoreceptor precursors to rod cell fate.17,18 A
deletion within the NR2E3 gene in the rd7 mouse is associated
with retinal degeneration,19,20 whereas sequence variants in
this gene in humans are associated with clinical phenotypes
including enhanced S cone syndrome (ESCS), Goldmann–
Favre syndrome, clumped pigmentary retinal degeneration and
autosomal dominant or recessive retinitis pigmentosa.21,22
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PNR and TLX regulate gene expression through recruit-
ment of corepressor complexes,22–24 and recently, we
demonstrated that these NRs interact directly with BCL11A/B
proteins,25 cofactors for the COUPTF/NR2F subfamily that
function in globin gene switching and neurogenesis.26,27
Indeed, we identified a novel motif (F/YSXLXXXL/Y) in
BCL11A/B and NSD1 proteins that facilitates their direct and
selective interactions with the NR2E/F subgroup.25 Although
monomeric TLX can bind 5′-AAGTCA-3′ half-sites in the
control regions of its target genes,11,28 PNR bind direct
repeats of 5′-ANGTCA-3′ sites separated by 1 bp (DR1) as
homodimers.15 This suggests that PNR and TLX may have
distinct dimerization capabilities, although this has not been
investigated systematically. Here we describe a systematic
analysis of PNR and TLX LBD interactions with other NRs and
present evidence for novel heterodimeric interactions of PNR
with PPARγ and TRβ.
Results
Distinct dimerization functions of the LBDs of human
PNR and TLX. We assessed the abilities of PNR and TLX
LBDs to form homo- or heterodimers in yeast two-hybrid
experiments, using a panel of human NR LBDs expressed as
AAD fusion proteins.25 Reporter activities were established
for transformed yeast clones cultured in the presence or
absence of agonist ligands for the partner LBDs, if known. As
shown in Figure 1a, the PNR hinge-LBD (131–410) construct
was able to form homodimers in the Y2H assays, consistent
with other studies using EMSA16 mammalian two hybrid29 or
BRET in mammalian cells.30 Moreover, strong activation of
the yeast reporter was observed when the LexA-PNR LBD
was co-expressed with the VP16 AAD-fused LBD of PPARγ
(but not either alone), suggesting direct association of the
LBDs of PNR and PPARγ. Similar levels of reporter activity
were observed in the presence or absence of the PPARγ
agonist rosiglitazone, indicating that in yeast cells, this
interaction is not dependent on addition of exogenous agonist
ligands. We also observed reporter activation (albeit weaker)
indicating interaction between the LBDs of PNR and NR1A2/
TRβ, upon addition of cognate ligand (T3) (Figure 1a). This
was confirmed using a near full-length VP16-TRβ1 construct,
which showed improved expression/stability in yeast. The
reporter activity was induced approximately 20-fold in the
presence of T3 (Supplementary Figure S1). Thus, PNR LBD
can heterodimerize with the ligand-bound TRβ LBD, another
NR known to be involved in the development of photorecep-
tors in the retina.31,32
We focused on characterization of the strongest interacting
pair in the Y2H assays, that is, PNR and PPARγ. To confirm
this interaction, we performed two-hybrid assays in the reverse
combination, that is, using LexA-PPARγ LBDwith the AAD-NR
LBD panel. Our previous studies indicated that yeast contains
endogenous agonists that stimulate strong interactions of
PPAR LBDs with SRC1 and TRAP220 cofactors,25,33 there-
fore it was only necessary to add exogenous ligands for the
partner LBDs (indicated by the red boxes in Figures 1a-c). As
shown in Figure 1b, the PPARγ LBD displayed strong
interactions with the LBDs of NR2B1/RXRα, NR0B1/DAX-1
and NR0B2/SHP consistent with other studies.9,34–36 Homo-
dimerization of the PPARγ LBD was also detected, and similar
levels of reporter activation were observed in the presence or
absence of rosiglitazone, confirming activation of PPARs by
endogenous ligands. Importantly, we also detected a strong
interaction with PNR LBD, thus confirming dimerization of
PPARγ and PNR in Y2H assays. Interestingly, we noted a
weak ligand-stimulated interaction of PPARγ with the LBD of
NR1B1/RARα, which to our knowledge has not been reported
previously, although it was not investigated further here.
We next tested the ability of the human TLX LBD to interact
with the same set of NRs. As a control, TLX LBD displayed
strong binding to the RID1 sequence of BCL11A comprising a
FSXXLXXL motif as previously reported.25 However, we did
not observe any evidence of interaction of the TLX LBD with
itself or any other NR LBD tested in these assays (Figure 1c).
This result supports previous studies suggesting that
vertebrate TLX functions as a monomer.11,16,37
The ability of PNR to associate with PPARγ LBD appeared
to be specific for this paralog, as no interaction was observed
with PPARα or PPARδ LBDs, whereas all three PPARs
showed robust interaction with the LBD of RXRα in the
absence of exogenous ligand (Figure 1d). We confirmed that
the PNR hinge domain (or D region) was neither necessary
nor sufficient for complex formation with PNR or PPARγ LBDs
(Supplementary Figure S2), supporting the hypothesis that the
interactions involve LBD heterodimers. These results con-
firmed that PNR LBD dimerization was not dependent on the
sequence corresponding to H1/H2 in other NR LBDs,
consistent with the reported crystal structure of a truncated
PNR LBD dimers lacking this sequence.29 GST pulldown
assays detected interactions of full-length His-tagged PNR
with the LBDs of PPARγ, TRβ and PNR, but not TLX
(Supplementary Figure S3) albeit difficult to demonstrate
ligand-stimulated effects in the in vitro assays, as reported in
other studies.38 Taken together, our results suggest the
existence of functional interactions of PNR with PPARγ and
TRβ, as a consequence of LBD-mediated heterodimer
formation. Interestingly, PPARγ, TRβ2 and PNR are each
implicated in the development and function of mammalian
retinal tissues39–41 although their direct interactions were not
previously known.
To validate the existence of PNR/PPARγ heterodimeric
complexes, co-immunoprecipitation assays were performed
on cell-free extracts of adult human retinal tissue. This tissue
was found to express PNR, TLX and PPARγ proteins as
determined by western blotting (Figure 1e; inputs). PNR was
readily immunoprecipitated from retinal extract, and western
blots confirmed co-immuno-precipitation of PPARγ, but not
TLX (Figure 1e). This result indicates the existence of PNR/
PPARγ complexes in adult human retinal tissue. We also
detected co-immunoprecipitation of endogenous PNR and
PPARγ proteins in the breast cancer cell line MDA-MB-468
(Supplementary Figure S4).
Retinopathy-associated PNR mutations perturb interac-
tions with PPARγ and BCL11A. Crystal structures of the
apo-LBDs of NR2E/F family members have been determined,
including COUPTFII, TLX and PNR.29,42,43 Along with others,
we have demonstrated that deletion of the AF2 helix perturbs
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the dimerization functions of the COUPTF-II LBD.25,43
Therefore, to probe the molecular interactions between the
PNR and PPARγ LBDs in more detail, we generated a LexA-
PNR LBD 192-399 mutant lacking the AF2 helix (ΔH12). In
addition, we constructed LexA-PNR LBD containing the
substitution mutation L375A. This residue lies within H10
and its substitution has been reported to impair homodimer
formation of PNR in vitro.29 Western blots revealed similar
expression levels of wild-type and PNR L375A construct in
yeast (see Supplementary Figure S5). Deletion of the AF2
helix (ΔH12) disrupted the ability of the PNR LBD to form
homodimers or heterodimers with the PPARγ LBD
(Figures 2a and e) as well as interactions with the RID
domain of its cofactor BCL11A (Figures 2b and e). This is
consistent with our previous observations for COUP-TFII LBD
homodimers in similar assays.25 As in other NRs, the PNR
AF2 sequence forms an amphipathic α-helix containing a
LXXLL-like motif (MXXLLXXM), which may stabilize the LBD
structure and cofactor binding via hydrophobic interactions.
However, we did not detect any interaction of a H12
sequence itself with PPARγ LBD (Supplementary Figure S2).
Replacement of L375 with alanine also strongly reduced the
heterodimerization with PPARγ LBD in two-hybrid assays
(Figures 2a and e), consistent with the location of this leucine
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Figure 1 Novel heterodimerization interactions within the NR superfamily. (a–c) Yeast two-hybrid assays on S. cerevisiae L40 cell-free extracts co-expressing LexA–DBD
fusion proteins containing the LBDs of PNR, PPARγ or TLX, in combination with a panel of AAD-NR LBDs. A single representative experiment is shown, and the data represent
the mean β-galactosidase activity of three independent clones, with error bars representing the S.D. For AAD-NR LBDs where a cognate ligand is known (i.e., those NRs within
the boxed area), assays were performed on cells cultured in the presence and absence of cognate ligands, as described in Materials and Methods. Note that LexA-DBD-PPARγ is
activated by endogenous agonists in yeast. (d) Yeast two-hybrid assays showing the specific LBD interactions of PNR and PPARγ, but not PPARα or PPARδ; the RXRα LBD is
shown to interact with all PPARs. (e) Co-immunoprecipitation of endogenous PNR and PPARγ proteins from retinal tissue lysate. Expression levels of PNR PPARγ and TLX
proteins in input samples are shown
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at the proposed interface of PNR LBD homodimers.29 The loss
of PPARγ LBD interactions suggests that similar molecular
surfaces are involved in homodimeric and heterodimeric
complexes of PNR, whereas the inability to bind the
corepressor motif may be due to perturbation of the cofactor
binding site, or failure of the mutant constructs to form LBD
dimers in the assay.
Clinical studies have identified a range of variants in the
NR2E3 gene coding sequence associated with human retinal
disease. These substitution mutations can perturb the
Figure 2 Disruption of PNR/PPARγ complexes by disease-associated mutations. Yeast two-hybrid assays showing interactions of LexA-PNR LBD constructs as indicated in
combination with (a) AAD -PPARγ LBD or (b) AAD-BCL11A 1-376 containing the RID motif. The L375A is designed to disrupt PNR dimerization via helix H10/11 and ΔH12 is a
C-terminally truncated mutant lacking the AF2 helix. (c) Interaction of LexA-PNR LBD wild-type or ESCS-associated variants with AAD-PPARγ LBD or (d) AAD-BCL11A 1-376.
(e) Qualitative summary of the effects of LBD variants on homodimer, heterodimer and corepressor interactions of PNR. (f) Schematic highlighting the differential effects of
W234S and L336P on dimerization and cofactor binding by the PNR LBD in Y2H assays. (g) Two-hybrid interactions of LexA-PPARγ LBD wild-type or mutant constructs with
VP16 AAD only (white bars) or AAD-PNR LBD or AAD-RXRα LBDs (black bars). Data are the average of triplicates and error bars represent S.D.
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functionality of the encoded PNR protein in transcriptional
activity, homodimer formation and binding of cofactors such as
atrophin.21,44 To assess how these sequence variants impact
on the ability of PNR LBD to associate with PPARγ, we
generated LexA-PNR LBD constructs comprising the most
commonly encountered ESCS-associated variants within this
domain, namely V232I, W234S, A256E, L263P, V302I,
R309G, R311Q, R334G, L336P, R385P and M407K. We also
generated PNR Q350R, which is associated with
Goldmann–Favre syndrome.45
Following co-transformation of L40 cells with AAD-PPARγ
LBD and either wild-type or mutant LexA-PNR LBD
constructs, Y2H assays revealed that several of the
ESCS-associated mutations strongly disrupted the interac-
tions of PNR and PPARγ LBDs (Figure 2c). A qualitative
summary is depicted in Figure 2e. Mutations that had a
strongly detrimental effect on PNR/PPARγ interactions were
L263P, R309G, L336P, R385P and M407K. In contrast,
W234S, A256E and Q350R generally displayed similar levels
of reporter activity as the wild-type PNR LBD, suggesting that
these substitutions do not substantially perturb the ability of
PNR LBD to associate with PPARγ in the assay. PNR LBDs
containing ESCS-associated mutations V232I, V302I, R311Q
and R334G retained PPARγ binding in this assay, albeit at
reduced levels as indicated by the reporter activities. Similar
effects of these mutations were observed regarding formation
of PNR LBD homodimer interactions, although A256E, R334G
and Q350R were more detrimental to PNR homodimer
formation (Figure 2e).
Several of the ESCS-associated mutations were also found
to disrupt binding to the corepressor BCL11A RID1 sequence
(Figure 2d), albeit with a distinct profile. In addition to L263P,
R309G, R385P and M407K, the mutants W234S and Q350R
showed strongly reduced interactions with the corepressor
peptide, while maintaining strong dimerization capabilities. In
contrast, L336P, which disrupted dimerization interactions,
had no negative effect on the RID1 binding. This differential
effect on the dimerization and cofactor binding functions of the
PNR LBD is shown schematically in Figure 2f. In summary, our
results indicate that ESCS-associated mutations in the
NR2E3 gene may not only impair PNR homodimer formation
and cofactor interactions, but also its ability to form
heterodimers with PPARγ.
Sequence alignments of the LBDs of the human NR2E/F
family reveal that several of the residues linked to retinopathy
variants are well conserved (Supplementary Figure S6). L263
(located in H5) is conserved amongst the NR2E/F family but is
replaced by alanine in the closest homologous group, that is,
the RXRs. R309 (H7) is also conserved, with lysine as the only
variant observed within this group. L336 (located in the turn
between H8 and H9) is replaced by phenylalanine in TLX,
although extended sequence in this loop region may account
for the inability of TLX LBD to dimerize. The H10 residue R385
is not conserved as it is replacedwith T,V, L or C residues in the
other members of the group, whereas M407 in the AF2 helix is
conserved among this subgroup of NRs.
We mapped the positions of variant residues using the
crystal structure of the PNR LBD (a.a. 217–410) homodimer
(PDB: 4LOG).29 The structure indicates that L263 is located in
helix H5 at the core of the LBD and is likely to stabilize the LBD
through multiple hydrophobic contacts (Supplementary
Figure S7A). Thus, insertion of proline at this position may
disrupt the LBD architecture and have catastrophic effects on
LBD functions. Another proline substitution involves residue
R385 located within H10/11, which forms the major dimer
interface between LBDs. R385 is located within the more
C-terminal portion of H10/11 (ref. 29) (Supplementary
Figure S7B). In one of the PNR LBD monomers, R385 makes
polar contacts with E299 (Supplementary Figure S7C), but
shows an alternative conformation in the partner LBD.
Although this residue is not well conserved in the NR2E/F
subfamily, proline substitution is likely to perturb the structure
because of steric clashes.
Interestingly, the PNR LBD L336P mutant maintained
strong binding to BCL11A peptide in our assays, indicating
at least partial function. This residue lies in the loop between
H8 and H9 (Supplementary Figures S6 and S7A) and despite
predicted steric clashes, the homologymodel suggests proline
may be accommodated without perturbing the overall LBD
structure (Supplementary Figure S7E). We superimposed the
structures of a single LBD in the PNR dimer (4LOG) with the
monomeric LBD of TLX/NR2E1 in complex with atrophin
cofactor peptide (PDB: 4XAJ)42 (Supplementary Figure S9).
Substantial overlap between the two structures was observed
and the alignment revealed that the LXXLXXY cofactor
peptide binding site is spatially distant from the L336P.
Assuming that cofactor peptides can associate with mono-
meric LBDs in the Y2H assays, this provides a plausible
explanation for the differential effect of L336P on cofactor
binding and dimerization.
Residue R309 is located within H7 and potentially makes
intramolecular polar contacts with L373, and intermolecular
polar contacts with E332 in the partner LBD (Supplementary
Figure S7D). The M407K mutation, which lies within the AF2
helix (H12), disrupted formation of PNR/PNR andPNR/PPARγ
LBD complexes in Y2H experiments (Figures 2c-e). Consis-
tent with this, deletion of the AF2 helix had a similar effect on
the formation of these complexes (Figures 2a and e).
However, it is unclear from the currently available ‘autore-
pressed’ structure how M407K impacts on LBD dimerization.
The PPARγ R425C mutation disrupts interaction with
PNR. Rare sequence variants in the PPARγ LBD, such as
V318M, F388L, R425C and P495L, are associated with
familial partial lipodystrophy type 3. These mutations have
been reported to have differential effects on PPARγ such as
impairment of transcriptional activity, ligand binding,
dimerization or corepressor dissociation,46,47 and thus are
generally associated with loss of function. We generated
AAD-PPARγ LBD mutants to assess the effects on associa-
tion with wild-type PNR LBD (Supplementary Figure S5B).
Interestingly, V318M, F388L and P495L mutants were able to
induce reporter activation to a level comparable to the wild-
type PPARγ LBD, indicating robust interaction with PNR LBD,
although in some replicate assays V318M showed a reduced
interaction (data not shown). In contrast, the R425C mutant
was significantly impaired in its ability to bind PNR LBD
(Figure 2g), whereas all the PPARγ constructs retained the
ability to interact with RXRα LBD (Figure 2g). Examination of
the crystal structure of the full-length PPARγ/RXRα complex
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in association with DNA48 reveals that the R425 residue
(which lies within a loop between helices H8 and H9) is
positioned close to the interface between PPARγ and RXRα
LBDs (see Supplementary Figure S8). The sidechain of R425
makes polar contacts with E352 in H4/5 of the PPARγ LBD,
but does not appear to contact RXRα LBD directly.38 Thus, a
pathogenic variant in the PPARγ LBD associated with partial
lipodystrophy can potentially impact on the formation of
PPARγ/PNR heterodimers.
NR2E3/PNR suppresses PPARγ-mediated reporter
activation. To examine the functional implications of PNR
interaction with PPARγ, we carried out mammalian cell
reporter assays. As in other studies,38 a reporter gene
controlled by a basal promoter with three copies of a DR1
element 5′-AGGTCAnAGGTCA-3′ (3xPPRE-tk-Luc) was
strongly activated by co-transfected FLAG-PPARγ in the
presence of rosiglitazone (Figure 3a). Co-transfection with
increasing amounts of PNR expression plasmid resulted in a
dose-dependent repression of PPARγ-activated reporter
activity. However, this repression was not observed when
the ESCS variant PNR R309G was co-expressed with PPARγ
under the same conditions. Western blots confirmed equal
expression of the WTand R309G proteins (Figure 3b). These
findings are consistent with reports that PNR can repress
some of its gene targets,15,17 potentially including PPARγ-
regulated genes as both NRs can bind DR1 elements. The
results also show that the PNR R309G variant negatively
impacts on the ability of PNR to repress PPARγ-mediated
transcription.
To explore possible mechanisms underlying the repression
of PPARγ reporter by PNR, we performed EMSA assays.
HEK293 cells were transfected with expression vectors for
PNR, FLAG-PPARγ or RXRα and nuclear extracts prepared
from the transfected cultures were admixed with a radiola-
beled double-stranded DR1 probe containing a consensus
PPAR response element (PPRE) (5′-nnnnAGGTCAaAG
GTCAnn-3′). As shown in Figure 3b, in mock-transfected
extracts, several bandswere observed because of association
of endogenous proteins with the DR1 probe (lane 1), which
may be endogenous NRs. However, western blots did not
detect any endogenous PNR proteins in HEK293 cells (data
not shown). Exogenously expressed wild-type PNRwas found
to associate strongly with the DR1 probe, and could be
supershifted by addition of PNR-specific antibody (compare
lanes 2 and 3). In contrast, PNR309Gwas unable to associate
with the DR1 probe, as no shifts were observed in the
presence or absence of antibody (lanes 7 and 8) consistent
with a previous study.21 Co-expression of FLAG-PPARγ with
PNR resulted in the formation of an additional second complex
of higher molecular weight, albeit of lower intensity and
partially masked by the PNR complex (lane 4). Addition of anti-
PNR antibody caused a supershift of the PNR complex
(lane 5), whereas FLAG antibody supershifted the remaining
higher molecular weight band (lane 6), indicating this higher
molecular weight complex contains FLAG-PPARγ. We sug-
gest that the FLAG-PPARγ complex (indicated by a white
asterix in lane 5) is probably formed by dimerization with
endogenous RXRs, which are required for PPARs to bind DNA
efficiently. Consistent with the hypothesis that formation of
PPARγ/DR1 complexes is limited by the availability of
endogenous RXRs in the extracts, co-transfection of a RXRα
and FLAG-PPARγ expression vectors resulted in a much
stronger shift of the probe because of binding of PPARγ/RXRα
heterodimers (compare lane 12 with 14 and 5), as confirmed
by supershift with the FLAG antibody (lanes 13 and 15).
Interestingly, although PNR309G alone failed to give a
detectable shift of the PPRE DR1 probe (lanes 7 and 8),
co-expression with FLAG-PPARγ yielded a strong complex of
similar molecular weight to transfected PPARγ/RXRα
complexes (lane 9). This complex (indicated by a red asterix;
Figure 3b) could be supershifted by either anti-PNR (lane 10)
or anti PPARγ antibodies (lane 11). This result suggests that
while defective homodimerization of the PNR (R309G) variant
compromises its ability to associate with a DR1 response
element in vitro, (note: there is no endogenous wild-type PNR)
it may be capable of forming heterodimeric associations with
PPARγ, at least in vitro. How this is achieved, and whether it
requires DNA-binding activity of the PNR variant remains to be
established.
In summary, as depicted schematically in Figure 4, we
conclude that PNR homodimers and PPARγ/RXRα
heterodimer complexes can assemble independently on
DR1 sequences, and therefore may compete for binding to
such sites in vivo (Figure 4a). Both dimers bound strongly
to canonical PPRE (5′-AGGTCAaAGGTCA-3′) (Figure 3b) or
to a PNRE (5′-AAGTCAaAAGTCA-3′) (data not shown)
probes in the EMSA assays. This may facilitate the assembly
of different NR/ cofactor complexes on target genes
(Figure 4b) in a tissue-specific or temporally regulated fashion.
Our study provides evidence for novel heterodimeric interac-
tions of PNR, PPARγ and TRβ, which may have important
implications for understanding their roles in disease.
Discussion
Although a subset of ligand-binding NRs have been well
characterized, the dimerization capabilities of most orphan
NRs have not been systematically studied. Here we used Y2H
and other assays to assess the LBD dimerization capabilities
of orphans PNR and TLX, which are predominantly expressed
in retinal and CNS tissues, respectively. TLX LBDdisplayed no
ability to form dimers with itself or other NRs, consistent with
suggestions that TLX functions as amonomer.11,28 Although a
recent crystal structure of a modified TLX LBD bound to a
corepressor peptide revealed a homodimeric LBD complex,
we note that it was necessary to modify nine residues within
the TLX LBD to resemble PNR surface residues, in addition to
removing the H1 and H2 helices to obtain crystals.42 Our
experiments failed to detect any evidence of dimer formation
by TLX LBD, although it readily bound to a corepressor motif,
in agreement with studies suggesting that vertebrate TLX
functions primarily as a monomer.37,49
Novel PNR heterodimer complexes. In addition to con-
firming PNR LBD homodimerization in our Y2H assays, we
observed novel heterodimeric interactions of PNR with
PPARγ and TRβ. Although PNR/TRβ association was ligand
dependent in yeast, PPARγ/PNR dimers formed indepen-
dently of exogenous ligand, likely due to the presence of
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endogenous PPAR agonists in yeast.2,25,50 These hetero-
dimer interactions required the integrity of the AF2 helix, and
were disrupted by mutations associated with human disease,
such as ESCS (PNR) or lipodystrophy (PPARγ) variants.
Like PNR, TRβ2 functions in photoreceptor development,41
and its disruption in mouse results in failure to express M
opsins, leading to a lack of M cones and an excess of S cone
photoreceptors.32 In addition to forming dimerswith RXRs and
itself, TRβ LBD has been reported to dimerize with Ear2/
NR2F651 and estrogen receptor ERα/NR3A152 although
interaction with NR2E3 has not been reported previously.
However, the paralog TRα has been reported to
Figure 3 Repression of PPARγ-mediated transcription by PNR. (a) Reporter assays showing ligand-dependent activation of a 3xPPRE-Luciferase by PPARγ in transiently
transfected U2OS cells and the effect of co-transfection of PNR wild-type and R309G expression vectors. Luciferase activity was normalized to the co-transfected β-galactosidase
activity. Reporter activity in transfected cells was determined following 24-h exposure to 10− 7M rosiglitazone or vehicle as indicated. Data show mean luciferase values from
triplicates assays, and error bars indicate the S.E.M. The right panel is a western blot showing detection of wild-type and R309G His-PNR proteins expressed in transfected cells,
detected with anti-PNR antibody. (b) EMSA assays and antibody supershifts showing binding of PNR wild-type or PNR (R309G), FLAG- PPARγ or RXRα to a DR1 element in the
combinations as indicated. Double-stranded DNA probes (end labeled with γ32P) were incubated with cell-free extracts of HEK293 cells expressing recombinant NR proteins, or
mock transfected as indicated (as described in Supplementary Materials and Methods). Free probes and specific NR/DNA and antibody complexes are indicated on the image.
The white asterix indicates a complex containing PPARγ that is shifted by the anti-FLAG antibody, the red asterix indicates complexes containing both PPARγ and PNR(R309G).
(c) Schematic representation depicting the proposed interactions of PNR and PNR(R309G) complexes with the DR1 probe
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heterodimerize with COUPTFs53 showing a precedence for
TR interactions with the NR2E/F subfamily. Thus, direct
interactions of PNR and TRβ2 may contribute to the regulation
of genes that determine photoreceptor fate.
Consistent with our findings, we note that PPARγ is reported
as a PNR-interacting protein in the BioGrid database, based
on global mammalian two-hybrid screen data deposited by the
FANTOM /RIKEN consortium.36 Although PNR and Reverbα/
NR1D1 were reported to co-regulate retinal genes,44,54 this
involved interactions via DBD and hinge regions of both NRs,
rather than the LBDs.55 Although we were unable to express a
stable NR1D1 LBD in our assays, we did not detect an
interaction of PNR with the paralog Rev-erbβ/NR1D2
(Figure 1a), even in the presence of exogenous heme
(data not shown), a ligand for Reverbs.56,57
PNR interaction with PPARγ: a potential role in ocular
disease?. Several NRs including PNR, TRβ2, RORs, TLX,
RXRs, RARs, ERRs, COUPTFs and Reverbs are implicated
in retinal development and function.41 Interestingly, PPARs
are also implicated in ocular diseases, including retinopa-
thies, diabetic retinopathy and age-related macular
degeneration.58 Therefore, our evidence for novel hetero-
dimeric interactions of PNR and PPARγ indicates a potentially
important intersection of these regulators in retina or other
tissues. PPARγ is expressed in rodent neuroretina and retinal
pigment epithelium, and several studies have indicated that
PPARγ agonists have protective effects for neuroretinal
damage in rodent models.40,59,60 PPARγ has been proposed
as a therapeutic target in ocular disease, because of its roles
in the regulation of oxidative stress and suppression of
VEGF-mediated neovascularization.39,40,61–63 In proliferative
diabetic retinopathy, thiazolidinediones can ameliorate
neovascularization by suppressing the expression of VEGF
and FLT1.60,64 Interestingly, FLT1 is also a target for
regulation by PNR.65
In addition to their direct physical interaction, PNR homo-
dimers and PPARγ/RXRα heterodimers associate with DR1
elements in vitro,15 and we have demonstrated that both can
bind canonical PPRE (Figure 3b) or PNRE elements (data not
shown) with similar efficacy. Indeed, PNR was able to repress
PPARγ-mediated activation of a PPRE reporter (Figure 3a).
However, the DNA-binding preferences and potential gene
targets of PNR/PPARγ heterodimers remains to be deter-
mined and warrants further investigation.
Effects of ESCS-associated mutations on PNR function.
Our results indicate that disease-associated LBD mutations
L263P, R309G, L336P, R385P and M407K have detrimental
effects on PNR function, in good agreement with previous
studies that have assessed PNR functionality with regard to
homodimer formation or binding of PNR to CRX, Rev-erbs,
atrophin, DNA or reporter gene repression assays.21,30,44,66
Fradot et al.66 showed that PNR carrying R385P or M407K
mutations lost the ability to repress a reporter gene, whereas
W234S and R311Q retained DNA-binding, homodimerization
and reporter gene repression functions. Although a GAL4-
PNR LBD fusion carrying R309G exhibited reduced repres-
sor activity compared with wild-type, this mutant was not
assessed in terms of DNA binding or in the context of full-
length PNR. Our data show that the R309G mutation perturbs
both homo- and heterodimerization of the PNR LBD in Y2H
assays (Figures 2c and e) and impairs the ability of full-length
PNR to bind DR1 and repress PPARγ-mediated reporter
Figure 4 Potential functional interactions of PNR complexes. Schematic model showing (a) proposed competition for DR1 type DNA targets; (b) possible role of PNR and
PPARγ complexes in cofactor switching. Red triangles denote agonist ligands. (c) Novel heterodimeric complexes involving PNR and possible competition with TRβ/RXR and
PPARγ⧸RXR heterodimers for dimeric partners. (d) Homology model of the PNR LBD (4LOG) indicating the distinct surfaces involved in dimerization and cofactor binding. The
cofactor peptide is from a superimposed alignment of the TLX LBD in complex with atrophin corepressor peptide (4XAJ)42
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activation (Figures 3a and b). Intriguingly, overexpression of
PPARγ rescued the ability of PNR (R309G) to associate with
DR1 complexes in EMSA experiments (Figure 3b). In
contrast to the Y2H assays, full-length PNR proteins in the
EMSA assays may help stabilize heterodimer interactions in
the EMSA assays.
Kanda and Swaroop21 reported that many NR2E3 clinical
variants impact on the subcellular localization of PNR,
resulting in increased localization to the cytoplasm to variable
extents, including W234S, A256E, L263P, R309G, R311Q,
R334G, L336P, R385P and M407K. This showed at least
partial correlation with loss of DNA-binding ability in EMSA
assays, with only V302I, R311Q, R334G and M407K retaining
DNA-binding activity but displaying reduced interaction with
CRX/NRL. PNR activation of a reporter gene was also
reduced by approximately twofold for most mutations with
the exceptions of V232I, W234S, R311Q and R334G.
Our Y2H data showed that reporter activation because of
PNR LBD homodimerization was an order of magnitude lower
than with PPARγ (Figures 1, 2 and data not shown). Although
V232I and W234S did not show any decreased interaction
compared with wild-type, qualitatively, most mutations per-
turbed PNR LBD homodimer formation in yeast, although
V302I and R311Q had only moderate impact. Moreover, our
data revealed differential effects on binding of the RID motif of
BCL11A (Figure 2d), a potent corepressor for the NR2E/F
family.25 Although L263P, R309G, R385P and M407K dis-
rupted BCL11A binding as may be expected, the mutants
W234S and Q350R also showed strongly reduced interaction
with the corepressor peptide. The Q350R mutation did not
hamper binding to PPARγ, consistent with its location away
from the dimerization interface. It is therefore possible that this
mutation impacts on cofactor recruitment. In contrast, L336P,
which disrupted PNR LBD dimerization interactions, had no
negative effect on the RID1 binding, highlighting that different
variants may invoke distinct functional impairments. Taken
together, these findings (summarized in Figure 4) suggest that
disease-associated variants in the NR2E3 gene not only
impair LBD homodimer and cofactor interactions, but also
impair heterodimer interactions with PPARγ or other NRs.
Although there was generally good agreement between
our studies and previous reports, different experimental
approaches or poor stability of mutant proteins may produce
discrepancies regarding the impact of different mutations.
Several groups22,29 have reported instability of PNR mutants,
and we also observed some evidence of this in some yeast
clones expressing R309G, R311Q and R334G constructs.
Therefore, we were careful to confirm equivalent expression
by western blots for any transformants included in reporter
assays (Supplementary Figure S5).
Mutations in PPARγ and lipodystrophy. PPARγ has
central roles in metabolic homeostasis through the regulation
of lipid and glucose metabolism. With the exception of the
P12A polymorphism, genetic variants in the PPARγ gene are
rare and LBD variants have been associated with familial
partial lipodystrophy type 3, leading to loss of fat tissues at
the extremities combined with insulin resistance and type 2
diabetes.46 These mutations generally result in loss of
function and reduced transcriptional activity of PPARγ. The
variants V318M, F388L and P495L reside in helices H3, H7
and H12, respectively, and have been reported to impact on
LBD functions other than dimerization.46 Our data reveal that
the R425C variant also has a detrimental effect on PPARγ
heterodimer interactions with PNR, whereas RXRα binding
was not significantly affected. Interestingly, retinal changes
are sometimes observed in patients with acquired partial
lipodystrophy.67,68 Crystal structures suggest that R425C
does not participate in direct contacts with the RXRα LBD,48
although it is located close to the heterodimer interface, and
therefore may have a role in contacting the PNR LBD.
Therefore, it is interesting to speculate on whether perturba-
tion of PNR/PPARγ heterodimers by genetic variants may
have a role in retinal changes in partial lipodystrophy
disorders.
In summary, although the major known function of PNR in
mammals is to orchestrate the photoreceptor differentiation,
PNR orthologs in frogs and fruitflies also function in the pineal
gland development, reproduction and circadian clock
function.69,70 Anatomical profiling has detected low level
NR2E3 expression in the enteric tract and in seminal
vesicles71 suggesting possible PNR functions in other tissues.
Moreover, cell line expression studies indicate co-expression
of PNR and PPARγ in cells of tumor origin. Thus, PNR and
PPARγ may converge to regulate genes in response to
developmental or pathogenic cues.
Materials and Methods
Detailed Materials and Methods for this study are available in the online
Supplementary Material.
Conflict of Interest
The authors declare no conflict of interest.
Acknowledgements. We are grateful to Eric Kalkhoven, Shiming Chen, Pierre
Chambon, Andy Bennett and other colleagues for gifts of reporter or expression
constructs. We thank the following students for assistance in experimental
replications: Christopher Roberts, Nunzia Rizzi, Vanessa Loczenski, Yinghua Quan,
and Valentina Mohamed Hashad. This work was supported by the Biotechnology and
Biological Sciences Research Council (grant number BB/J014508/1), by a BBSRC
DTP studentship to JW; Cancer Research UK (grant number C1506/A11643); and
Leukaemia Lymphoma Research (grant number 06090), by a Gordon Pillar
Studentship to CMC. CJM was supported by a PhD studentship from CAPES, Brazil;
BM was supported by a University of Nottingham Vice Chancellor’s scholarship. JF
was funded by a PhD studentship from the Royal Pharmaceutical Society of Great
Britain via an Academic Excellence Award to DMH.
1. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K et al. The nuclear
receptor superfamily: the second decade. Cell 1995; 83: 835–839.
2. Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional
co-activators mediates binding to nuclear receptors. Nature 1997; 387: 733–736.
3. Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK et al. The transcriptional
co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 1997; 387:
677–684.
4. Kalkhoven E, Valentine JE, Heery DM, Parker MG. Isoforms of steroid receptor co-activator 1
differ in their ability to potentiate transcription by the oestrogen receptor. EMBO J 1998; 17:
232–243.
5. Hu X, Lazar MA. The CoRNR motif controls the recruitment of corepressors by nuclear
hormone receptors. Nature 1999; 402: 93–96.
6. Germain P, Staels B, Dacquet C, Spedding M, Laudet V. Overview of nomenclature of
nuclear receptors. Pharmacol Rev 2006; 58: 685–704.
7. Brelivet Y, Kammerer S, Rochel N, Poch O, Moras D. Signature of the oligomeric behaviour
of nuclear receptors at the sequence and structural level. EMBO Rep 2004; 5: 423–429.
Novel PNR/PPARγ heterodimers
J Fulton et al
9
Cell Death and Disease
8. Rastinejad F, Huang P, Chandra V, Khorasanizadeh S. Understanding nuclear receptor form
and function using structural biology. J Mol Endocrinol 2013; 51: T1–T21.
9. Albers M, Kranz H, Kober I, Kaiser C, Klink M, Suckow J et al. Automated yeast
two-hybrid screening for nuclear receptor-interacting proteins. Mol Cell Proteomics 2005; 4:
205–213.
10. Weber KP, Alvaro CG, Baer GM, Reinert K, Cheng G, Clever S et al. Analysis of C. elegans
NR2E nuclear receptors defines three conserved clades and ligand-independent functions.
BMC Evol Biol 2012; 12: 81.
11. Yu RT, Chiang MY, Tanabe T, Kobayashi M, Yasuda K, Evans RM et al. The orphan nuclear
receptor Tlx regulates Pax2 and is essential for vision. Proc Natl Acad Sci USA 2000;
97: 2621–2625.
12. Zhang CL, Zou Y, Yu RT, Gage FH, Evans RM. Nuclear receptor TLX prevents retinal
dystrophy and recruits the corepressor atrophin1. Genes Dev 2006; 20: 1308–1320.
13. Young KA, Berry ML, Mahaffey CL, Saionz JR, Hawes NL, Chang B et al. Fierce: a new
mouse deletion of Nr2e1; violent behaviour and ocular abnormalities are background-
dependent. Behav Brain Res 2002; 132: 145–158.
14. Zhang CL, Zou Y, He W, Gage FH, Evans RM. A role for adult TLX-positive neural stem cells
in learning and behaviour. Nature 2008; 451: 1004–1007.
15. Chen F, Figueroa DJ, Marmorstein AD, Zhang Q, Petrukhin K, Caskey CT et al.
Retina-specific nuclear receptor: a potential regulator of cellular retinaldehyde-binding
protein expressed in retinal pigment epithelium and Muller glial cells. Proc Natl Acad Sci USA
1999; 96: 15149–15154.
16. Kobayashi M, Takezawa S, Hara K, Yu RT, Umesono Y, Agata K et al. Identification
of a photoreceptor cell-specific nuclear receptor. Proc Natl Acad Sci USA 1999; 96:
4814–4819.
17. Chen J, Rattner A, Nathans J. The rod photoreceptor-specific nuclear receptor Nr2e3
represses transcription of multiple cone-specific genes. J Neurosci 2005; 25: 118–129.
18. Peng GH, Ahmad O, Ahmad F, Liu J, Chen S. The photoreceptor-specific nuclear receptor
Nr2e3 interacts with Crx and exerts opposing effects on the transcription of rod versus
cone genes. Hum Mol Genet 2005; 14: 747–764.
19. Haider NB, Jacobson SG, Cideciyan AV, Swiderski R, Streb LM, Searby C et al.Mutation of a
nuclear receptor gene, NR2E3, causes enhanced S cone syndrome, a disorder of retinal
cell fate. Nat Genet 2000; 24: 127–131.
20. Akhmedov NB, Piriev NI, Chang B, Rapoport AL, Hawes NL, Nishina PM et al. A deletion in a
photoreceptor-specific nuclear receptor mRNA causes retinal degeneration in the
rd7 mouse. Proc Natl Acad Sci USA 2000; 97: 5551–5556.
21. Kanda A, Swaroop A. A comprehensive analysis of sequence variants and putative
disease-causing mutations in photoreceptor-specific nuclear receptor NR2E3. Mol Vision
2009; 15: 2174–2184.
22. Escher P, Gouras P, Roduit R, Tiab L, Bolay S, Delarive T et al. Mutations in NR2E3 can
cause dominant or recessive retinal degenerations in the same family. Hum Mutat 2009;
30: 342–351.
23. Takezawa S, Yokoyama A, Okada M, Fujiki R, Iriyama A, Yanagi Y et al. A cell
cycle-dependent co-repressor mediates photoreceptor cell-specific nuclear receptor
function. EMBO J 2007; 26: 764–774.
24. Wang L, Rajan H, Pitman JL, McKeown M, Tsai CC. Histone deacetylase-associating
atrophin proteins are nuclear receptor corepressors. Genes Dev 2006; 20: 525–530.
25. Chan CM, Fulton J, Montiel-Duarte C, Collins HM, Bharti N, Wadelin FR et al. A signature
motif mediating selective interactions of BCL11A with the NR2E/F subfamily of orphan
nuclear receptors. Nucleic Acids Res 2013; 41: 9663–9679.
26. Avram D, Fields A, Pretty On Top K, Nevrivy DJ, Ishmael JE, Leid M. Isolation of a novel
family of C(2)H(2) zinc finger proteins implicated in transcriptional repression mediated by
chicken ovalbumin upstream promoter transcription factor (COUP-TF) orphan nuclear
receptors. J Biol Chem 2000; 275: 10315–10322.
27. Sankaran VG, Menne TF, Xu J, Akie TE, Lettre G, Van Handel B et al. Human fetal
hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A.
Science 2008; 322: 1839–1842.
28. Schmouth JF, Arenillas D, Corso-Diaz X, Xie YY, Bohacec S, Banks KG et al. Combined
serial analysis of gene expression and transcription factor binding site prediction identifies
novel-candidate-target genes of Nr2e1 in neocortex development. BMC Genomics 2015;
16: 545.
29. Tan MH, Zhou XE, Soon FF, Li X, Li J, Yong EL et al. The crystal structure of the orphan
nuclear receptor NR2E3/PNR ligand binding domain reveals a dimeric auto-repressed
conformation. PloS ONE 2013; 8: e74359.
30. Roduit R, Escher P, Schorderet DF. Mutations in the DNA-binding domain of NR2E3 affect
in vivo dimerization and interaction with CRX. PloS ONE 2009; 4: e7379.
31. Swaroop A, Kim D, Forrest D. Transcriptional regulation of photoreceptor development and
homeostasis in the mammalian retina. Nat Rev Neurosci 2010; 11: 563–576.
32. Ng L, Hurley JB, Dierks B, Srinivas M, Salto C, Vennstrom B et al. A thyroid hormone
receptor that is required for the development of green cone photoreceptors. Nat Genet 2001;
27: 94–98.
33. Coulthard VH, Matsuda S, Heery DM. An extended LXXLL motif sequence determines
the nuclear receptor binding specificity of TRAP220. J Biol Chem 2003; 278:
10942–10951.
34. Nishizawa H, Yamagata K, Shimomura I, Takahashi M, Kuriyama H, Kishida K et al.
Small heterodimer partner, an orphan nuclear receptor, augments peroxisome proliferator-
activated receptor gamma transactivation. J Biol Chem 2002; 277: 1586–1592.
35. Issemann I, Prince RA, Tugwood JD, Green S. The retinoid X receptor enhances the function
of the peroxisome proliferator activated receptor. Biochimie 1993; 75: 251–256.
36. Ravasi T, Suzuki H, Cannistraci CV, Katayama S, Bajic VB, Tan K et al. An atlas of
combinatorial transcriptional regulation in mouse and man. Cell 2010; 140: 744–752.
37. Yu RT, McKeown M, Evans RM, Umesono K. Relationship between Drosophila gap gene
tailless and a vertebrate nuclear receptor Tlx. Nature 1994; 370: 375–379.
38. Jeninga EH, van Beekum O, van Dijk AD, Hamers N, Hendriks-Stegeman BI, Bonvin AM
et al. Impaired peroxisome proliferator-activated receptor gamma function through mutation
of a conserved salt bridge (R425C) in familial partial lipodystrophy. Mol Endocrinol 2007; 21:
1049–1065.
39. Song MK, Roufogalis BD, Huang TH. Modulation of diabetic retinopathy pathophysiology by
natural medicines through PPAR-gamma-related pharmacology. Br J Pharmacol 2012; 165:
4–19.
40. Herzlich AA, Ding X, Shen D, Ross RJ, Tuo J, Chan CC. Peroxisome proliferator-activated
receptor expression in murine models and humans with age-related macular degeneration.
Open Biol J 2009; 2: 141–148.
41. Forrest D, Swaroop A. Minireview: the role of nuclear receptors in photoreceptor
differentiation and disease. Mol Endocrinol 2012; 26: 905–915.
42. Zhi X, Zhou XE, He Y, Searose-Xu K, Zhang CL, Tsai CC et al. Structural basis for
corepressor assembly by the orphan nuclear receptor TLX. Genes Dev 2015; 29: 440–450.
43. Kruse SW, Suino-Powell K, Zhou XE, Kretschman JE, Reynolds R, Vonrhein C et al.
Identification of COUP-TFII orphan nuclear receptor as a retinoic acid-activated receptor.
PLoS Biol 2008; 6: e227.
44. von Alpen D, Tran HV, Guex N, Venturini G, Munier FL, Schorderet DF et al. Differential
dimerization of variants linked to enhanced S-cone sensitivity syndrome (ESCS) located in
the NR2E3 ligand-binding domain. Hum Mutat 2015; 36: 599–610.
45. Pachydaki SI, Klaver CC, Barbazetto IA, Roy MS, Gouras P, Allikmets R et al. Phenotypic
features of patients with NR2E3 mutations. Arch Ophthalmol 2009; 127: 71–75.
46. Jeninga EH, Gurnell M, Kalkhoven E. Functional implications of genetic variation in human
PPARgamma. Trends Endocrinol Metabol 2009; 20: 380–387.
47. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA et al. Dominant
negative mutations in human PPARgamma associated with severe insulin resistance,
diabetes mellitus and hypertension. Nature 1999; 402: 880–883.
48. Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, Burris TP et al. Structure
of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA. Nature 2008; 456:
350–356.
49. DeMeo SD, Lombel RM, Cronin M, Smith EL, Snowflack DR, Reinert K et al. Specificity of
DNA-binding by the FAX-1 and NHR-67 nuclear receptors of Caenorhabditis elegans is
partially mediated via a subclass-specific P-box residue. BMC Mol Biol 2008; 9: 2.
50. Heery DM, Hoare S, Hussain S, Parker MG, Sheppard H. Core LXXLL motif sequences in
CREB-binding protein, SRC1, and RIP140 define affinity and selectivity for steroid and
retinoid receptors. J Biol Chem 2001; 276: 6695–6702.
51. Zhu XG, Park KS, Kaneshige M, Bhat MK, Zhu Q, Mariash CN et al. The orphan nuclear
receptor Ear-2 is a negative coregulator for thyroid hormone nuclear receptor function. Mol
Cell Biol 2000; 20: 2604–2618.
52. Lee SK, Choi HS, Song MR, Lee MO, Lee JW. Estrogen receptor, a common interaction
partner for a subset of nuclear receptors. Mol Endocrinol 1998; 12: 1184–1192.
53. Berrodin TJ, Marks MS, Ozato K, Linney E, Lazar MA. Heterodimerization among thyroid
hormone receptor, retinoic acid receptor, retinoid X receptor, chicken ovalbumin upstream
promoter transcription factor, and an endogenous liver protein. Mol Endocrinol 1992; 6:
1468–1478.
54. Mollema NJ, Yuan Y, Jelcick AS, Sachs AJ, von Alpen D, Schorderet D et al. Nuclear
receptor Rev-erb alpha (Nr1d1) functions in concert with Nr2e3 to regulate transcriptional
networks in the retina. PloS ONE 2011; 6: e17494.
55. Cheng H, Khanna H, Oh EC, Hicks D, Mitton KP, Swaroop A. Photoreceptor-specific nuclear
receptor NR2E3 functions as a transcriptional activator in rod photoreceptors. Hum Mol
Genet 2004; 13: 1563–1575.
56. Yin L, Wu N, Curtin JC, Qatanani M, Szwergold NR, Reid RA et al. Rev-erbalpha,
a heme sensor that coordinates metabolic and circadian pathways. Science 2007; 318:
1786–1789.
57. Raghuram S, Stayrook KR, Huang P, Rogers PM, Nosie AK, McClure DB et al. Identification
of heme as the ligand for the orphan nuclear receptors REV-ERBalpha and REV-ERBbeta.
Nat Struct Mol Biol 2007; 14: 1207–1213.
58. Malek G, Lad EM. Emerging roles for nuclear receptors in the pathogenesis of age-related
macular degeneration. Cell Mol Life Sci 2014; 71: 4617–4636.
59. Zhu J, Zhang J, Ji M, Gu H, Xu Y, Chen C et al. The role of peroxisome proliferator-activated
receptor and effects of its agonist, pioglitazone, on a rat model of optic nerve crush:
PPARgamma in retinal neuroprotection. PloS ONE 2013; 8: e68935.
60. Pershadsingh HA, Moore DM. PPARgamma agonists: potential as therapeutics for
neovascular retinopathies. PPAR Res 2008; 2008: 164273.
61. Ciudin A, Hernandez C, Simo R. Molecular implications of the PPARs in the diabetic eye.
PPAR Res 2013; 2013: 686525.
62. Zhang S, Gu H, Hu N. Role of peroxisome proliferator-activated receptor gamma in ocular
diseases. J Ophthalmol 2015; 2015: 275435.
63. Al-Shabrawey M, Elsherbiny M, Nussbaum J, Othman A, Megyerdi S, Tawfik A. Targeting
neovascularization in ischemic retinopathy: recent advances. Expert Rev Ophthalmol 2013;
8: 267–286.
Novel PNR/PPARγ heterodimers
J Fulton et al
10
Cell Death and Disease
64. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator-activated receptor gamma
ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999; 274:
9116–9121.
65. Owen LA, Morrison MA, Ahn J, Woo SJ, Sato H, Robinson R et al. FLT1 genetic
variation predisposes to neovascular AMD in ethnically diverse populations
and alters systemic FLT1 expression. Invest Ophthalmol Visual Sci 2014; 55:
3543–3554.
66. Fradot M, Lorentz O, Wurtz JM, Sahel JA, Leveillard T. The loss of transcriptional inhibition
by the photoreceptor-cell specific nuclear receptor (NR2E3) is not a necessary cause of
enhanced S-cone syndrome. Mol Vision 2007; 13: 594–601.
67. Broadhead GK, Chang A. Choroidal neovascularization in acquired partial lipodystrophy. Eur
J Ophthalmol 2013; 23: 439–441.
68. Jansen J, Delaere L, Spielberg L, Leys A. Long-term fundus changes in acquired partial
lipodystrophy. BMJ Case Rep 2013; 2013: bcr2013201218.
69. Martinez-De Luna RI, El-Hodiri HM. The Xenopus ortholog of the nuclear hormone
receptor Nr2e3 is primarily expressed in developing photoreceptors. Int J Dev Biol 2007; 51:
235–240.
70. Bates KE, Molnar J, Robinow S. The unfulfilled gene and nervous system development in
Drosophila. Biochim Biophys Acta 2015; 1849: 217–223.
71. Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ. Anatomical profiling of
nuclear receptor expression reveals a hierarchical transcriptional network. Cell 2006;
126: 789–799.
Cell Death and Disease is an open-access journal
published by Nature Publishing Group. This work is
licensed under a Creative Commons Attribution 4.0 International
License. The images or other third party material in this article are
included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the
Creative Commons license, users will need to obtain permission from
the license holder to reproduce the material. To view a copy of this
license, visit http://creativecommons.org/licenses/by/4.0/
r The Author(s) 2017
Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)
Novel PNR/PPARγ heterodimers
J Fulton et al
11
Cell Death and Disease
